Home/Filings/4/0001209191-23-049362
4//SEC Filing

Farwell Wildon 4

Accession 0001209191-23-049362

CIK 0001818794other

Filed

Sep 12, 8:00 PM ET

Accepted

Sep 13, 7:56 PM ET

Size

5.8 KB

Accession

0001209191-23-049362

Insider Transaction Report

Form 4
Period: 2023-09-12
Farwell Wildon
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2023-09-12$10.41/sh1,707$17,77089,250 total
Footnotes (3)
  • [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.07 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
  • [F3]Includes 66,799 unvested RSUs.

Issuer

Dyne Therapeutics, Inc.

CIK 0001818794

Entity typeother

Related Parties

1
  • filerCIK 0001847941

Filing Metadata

Form type
4
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 7:56 PM ET
Size
5.8 KB